Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer

NCT04799431 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study never started

Conditions

Pancreatic Cancer Metastatic
Colorectal Cancer Metastatic

Interventions

DRUG: Neoantigen Vaccine with Poly-ICLC adjuvant
DRUG: Retifanlimab

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]